189 related articles for article (PubMed ID: 15627182)
21. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.
Janson ET; Kälkner KM; Eriksson B; Westlin JE; Oberg K
Nucl Med Biol; 1999 Nov; 26(8):877-82. PubMed ID: 10708300
[TBL] [Abstract][Full Text] [Related]
23. Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT.
Ruf J; Steffen I; Mehl S; Rosner C; Denecke T; Pape UF; Plotkin M; Amthauer H
Nucl Med Commun; 2007 Oct; 28(10):782-8. PubMed ID: 17728608
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of
Ortiz S; García JR; Riera E; Soler M; Compte Montañez A; Valls E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):244-245. PubMed ID: 32089469
[No Abstract] [Full Text] [Related]
25. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
[TBL] [Abstract][Full Text] [Related]
26. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms.
Even-Sapir E; Keidar Z; Sachs J; Engel A; Bettman L; Gaitini D; Guralnik L; Werbin N; Iosilevsky G; Israel O
J Nucl Med; 2001 Jul; 42(7):998-1004. PubMed ID: 11438618
[TBL] [Abstract][Full Text] [Related]
27. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
[TBL] [Abstract][Full Text] [Related]
28. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
29. Octreotide imaging plus bone scintigrams to optimally localize gastroenteropancreatic neuroendocrine tumors.
Le Duc-Pennec A; Thol C; Cavarec M; Le Rest C; Turzo A; Guillo P; Bizais Y
Clin Nucl Med; 2003 Jan; 28(1):5-8. PubMed ID: 12493952
[TBL] [Abstract][Full Text] [Related]
30. [Bronchial carcinoid tumor and scintigraphy of somatostatin receptors: detection of bone metastasis].
Banzo J; Abós MD; Prats E; García F; Freile E; Razola P; Escalera T
Rev Esp Med Nucl; 2001 Oct; 20(6):431-8. PubMed ID: 11578577
[TBL] [Abstract][Full Text] [Related]
31. Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy.
Moreira AP; Duarte LH; Vieira F; João F; Lima JP
Rev Esp Med Nucl; 2005; 24(1):14-8. PubMed ID: 15701341
[TBL] [Abstract][Full Text] [Related]
32. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
33. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
Pauwels S; Leners N; Fiasse R; Jamar F
Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
[No Abstract] [Full Text] [Related]
34. 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.
Bombardieri E; Chiti A; Crippa F; Seregni E; Cataldo I; Maffioli L; Soresi E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):104-7. PubMed ID: 9002763
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ultrasonography, computed tomography, and single-photon emission computed tomography for the detection and localization of canine insulinoma.
Robben JH; Pollak YW; Kirpensteijn J; Boroffka SA; van den Ingh TS; Teske E; Voorhout G
J Vet Intern Med; 2005; 19(1):15-22. PubMed ID: 15715042
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.
Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; Reubi JC; Lamberts SW
Ann N Y Acad Sci; 1994 Sep; 733():416-24. PubMed ID: 7978890
[No Abstract] [Full Text] [Related]
37. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours.
Hillel PG; van Beek EJ; Taylor C; Lorenz E; Bax ND; Prakash V; Tindale WB
Clin Radiol; 2006 Jul; 61(7):579-87. PubMed ID: 16784943
[TBL] [Abstract][Full Text] [Related]
38. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
39. SPET/CT image co-registration in the abdomen with a simple and cost-effective tool.
Förster GJ; Laumann C; Nickel O; Kann P; Rieker O; Bartenstein P
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):32-9. PubMed ID: 12483407
[TBL] [Abstract][Full Text] [Related]
40. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis.
Ingui CJ; Shah NP; Oates ME
Clin Nucl Med; 2006 Nov; 31(11):665-72. PubMed ID: 17053381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
